BioSpace News Archive

Drug Development

Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor

Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been dosed in the Phase 1/2 trial of TSN1611 for the treatment of KRAS G12D mutant solid tumors in the United States.

May 24, 2024
·
2 min read
Pharm Country

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

Shanghai Henlius Biotech, Inc. and Organon announced that the European Medicines Agency has validated the marketing authorization applications for HLX14, an investigational Prolia® and Xgeva® biosimilar.

May 24, 2024
·
7 min read
BioCapital

AbelZeta Announces Publication of Abstract for ASCO 2024 Annual Meeting

AbelZeta Pharma, Inc. announced that data from its C-CAR031 study has been published in an abstract available on the 2024 American Society of Clinical Oncology’s official website, in connection with the Company’s oral presentation at the ASCO Annual Meeting taking place in Chicago May 31 to June 4, 2024.

May 24, 2024
·
3 min read
Drug Development

HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress

Human Immunology Biosciences announced positive interim results from the randomized, placebo-controlled Phase 2 IGNAZ study of the investigational CD38 antibody felzartamab in the treatment of IgA nephropathy.

May 24, 2024
·
6 min read
hC Bioscience Announces Program in Duchenne Muscular Dystrophy and Reports In Vivo Data From tRNA-based Protein Editing Platform

hC Bioscience, a biopharmaceutical company developing a fundamentally novel approach to treating genetic diseases through tRNA-based protein editing

May 24, 2024
·
1 min read
Drug Development

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

BridgeBio Pharma, Inc. announced that 12 oral and moderated poster presentations will be shared at the 2024 International Symposium on Amyloidosis, taking place in Rochester, Minnesota on May 26 - 30, 2024.

May 24, 2024
·
5 min read
Drug Development

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

CG Oncology, Inc. announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ.

May 24, 2024
·
7 min read
Pharm Country

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

IN8bio, Inc. a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28th to June 1st in Vancouver, Canada.

May 24, 2024
·
4 min read
American Aires Extends Global Expansion by Opening Latest International Fulfillment Center in the UK

American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (“Aires” or the “Company”), a pioneer in cutting-edge technology designed to protect against electromagnetic

May 24, 2024
·
7 min read
Creative Proteomics Introduces Advanced GST Pull-Down Service for Protein Interaction Studies

Creative Proteomics, a renowned leader in proteomics services, is making waves in the field of protein interaction studies with its cutting-edge GST Pull-Down Service.

May 24, 2024
·
3 min read